Ignite Creation Date:
2025-12-25 @ 5:19 AM
Ignite Modification Date:
2025-12-26 @ 4:26 AM
Study NCT ID:
NCT00244127
Status:
UNKNOWN
Last Update Posted:
2005-10-28
First Post:
2005-10-24
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Open Label, Single Arm, Phase II Study Using R-COMP in Elderly Patients With Aggressive NHL.
Sponsor:
Zeneus Pharma
Organization:
Study Overview
Official Title:
Cyclophosphamide, Oncovin, Myocet, Prednisone and Rituximab (R-COMP) in the Treatment of Elderly Patients With Aggressive NHL.
Status:
UNKNOWN
Status Verified Date:
2005-10
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the safety and efficacy of R-COMP in elderly patients with advanced aggressive NHL. Myocet (non-pegylated liposomal doxorubicin) replaces conventional doxorubicin in the R-CHOP regimen.
Detailed Description:
To evaluate the duration of remission, disease free survival and 2-year survival of R-COMP in first line therapy of elderly patients with advanced aggressive NHL.
To evaluate the tolerability of R-COMP in first line therapy of elderly patients with advanced aggressive NHL.
To evaluate the tolerability of R-COMP in first line therapy of elderly patients with advanced aggressive NHL.
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| The MYOCAN Study | None | None | View |